Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · IEX Real-Time Price · USD
8.11
+0.46 (6.01%)
At close: May 1, 2024, 4:00 PM
8.13
+0.02 (0.25%)
Pre-market: May 2, 2024, 5:06 AM EDT
Addex Therapeutics Revenue
In the year 2023, Addex Therapeutics had annual revenue of $1.96M with 26.20% growth. Revenue in the quarter ending December 31, 2023 was $218.84K, a -66.02% decrease year-over-year.
Revenue (ttm)
$1.96M
Revenue Growth
+26.20%
P/S Ratio
6.44
Revenue / Employee
$85,252
Employees
23
Market Cap
12.62M USD
Revenue Chart
* The company reports in CHF currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.96M | 407.08K | 26.20% |
| Dec 31, 2022 | 1.55M | -1.91M | -55.16% |
| Dec 31, 2021 | 3.47M | -942.95K | -21.39% |
| Dec 31, 2020 | 4.41M | 1.49M | 50.90% |
| Dec 31, 2019 | 2.92M | -3.92M | -57.29% |
| Dec 31, 2018 | 6.84M | 6.33M | 1,233.43% |
| Dec 31, 2017 | 512.92K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telesis Bio | 27.51M |
| Guardion Health Sciences | 12.25M |
| BioCardia | 477.00K |
| Inhibikase Therapeutics | 260.50K |
| China SXT Pharmaceuticals | 29.92K |
ADXN News
- 3 days ago - Addex Provides Update on ADX71149 Phase 2 Epilepsy Study - GlobeNewsWire
- 13 days ago - Addex to Present at the Swiss Biotech Day 2024 - GlobeNewsWire
- 14 days ago - Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 - GlobeNewsWire
- 4 weeks ago - Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders - GlobeNewsWire
- 7 weeks ago - Addex to Present at the Bio-Europe Spring 2024 Conference - GlobeNewsWire
- 3 months ago - Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC. - GlobeNewsWire
- 4 months ago - Addex to Present at the Swiss Equities Baader Conference - GlobeNewsWire